VanEck Associates
BIVV

VanEck Associates’s Bioverativ Inc. Common Stock BIVV Stock Holding History

VanEck Associates’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-987
Closed -$53K – 770
2017
Q4 		$53K Sell
987
-117
-11% -$6.4K ﹤0.01% 657
2017
Q3 		$63K Buy
1,104
+159
+17% +$9.31K ﹤0.01% 687
2017
Q2 		$57K Sell
945
-184
-16% -$10.5K ﹤0.01% 701
2017
Q1 		$61K Buy
+1,129
New +$55.6K ﹤0.01% 790

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

VanEck Associates's BIVV Position: Q1 2018 in Review

VanEck Associates sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 987 shares — an estimated $53K sold.

VanEck Associates first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $63K in Q3 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • VanEck Associates reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • VanEck Associates sold 987 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $53K.
  • VanEck Associates first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • VanEck Associates's Bioverativ Inc. Common Stock position peaked at $63K in Q3 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on VanEck Associates's 13F filing for Q1 2018, filed 11 May 2018.